Leon Chen

Managing Partner at Kayne Anderson Capital Advisors, L.P.

Leon Chen is a prominent figure in the biotechnology and venture capital sectors, currently serving as a Board Observer at Sapience. He holds a PhD in Molecular Pharmacology from Stanford University and has a robust background in both entrepreneurship and investment.

Professional Background::

Current Role: Board Observer at Sapience, where he contributes insights from his extensive experience in biotech.
Previous Experience:
- Venture Partner at OrbiMed, focusing on early-stage biotech investments and company creation.
- Partner at Skyline Ventures and Entrepreneur in Residence at Venrock, where he played key roles in various biotech ventures.
- Founder of KAI Pharmaceuticals, which was acquired by Amgen, leading to the approval of the drug Parsabiv in multiple regions including the US and Europe.

Education::

BA in Biochemistry from UC Berkeley.
PhD in Molecular Pharmacology from Stanford School of Medicine.
MBA from Stanford Graduate School of Business.

Board Memberships:: Dr. Chen also serves on the boards of several companies, including Eikon Therapeutics and Tr1X Bio, showcasing his influence and leadership within the biotech community.1